新辅助化疗治疗晚期子宫内膜癌患者的疗效及对患者血清CA19-9、HE4、TGF-β1水平的影响

doi:10.3969/j.issn.1671-7171.2023.03.005

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1134 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To study the effects of neoadjuvant chemotherapy (NACT) on serum carbohydrate antigen 199 (CA19-9),human epididymal protein 4 (HE4) and transforming growth factor-β1 (TGF-β1) in the treatment of advanced endometrial carcinoma (EC). 【Methods】 A total of 112 patients with advanced EC treated in Second Hospital of Yulin from January 2015 to December 2019 were selected and divided into the observation group and the control group according to random number table method,with 56 patients in each group. The two groups underwent laparoscopic radical gastrectomy for endometrial cancer. The observation group received NACT before surgery and routine chemotherapy after surgery,while the control group only received routine chemotherapy after surgery. Operation related indicators,serum CA19-9,HE4,TGF-β1 and other tumor markers before and after treatment,the toxicity (Ⅲ-Ⅳ) and 3-year survival of the two groups were observed and compared. 【Results】 The intraoperative blood loss,operation time and hospitalization time of the observation group were all less than those of the control group,and the differences were statistically significant (P<0.05). After treatment,the levels of serum CA19-9,HE4 and TGF-β1 in the observation group were lower than those in control group (P<0.05). There was no difference in toxicities of Ⅲ to Ⅳ between the two groups (P>0.05). There was no difference in 3-year survival rate between the two groups (P>0.05). 【Conclusion】 NACT treatment for advanced EC can reduce the non-operable lesions to operable ones,and can inhibit levels of CA19-9,HE4,and TGF-β1 with no significant increase in toxicity.

Key words： Endometrial Neoplasms Chemotherapy,Adjuvant CA19-9 Antigen/BL Epididymal Secretory Proteins/BL Transforming Growth Factor beta1/BL

Received: 17 December 2021

PACS:

R737.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yu-ping
	KANG Hong-mei

Cite this article:

WANG Yu-ping,KANG Hong-mei. Neoadjuvant Chemotherapy for Advanced Endometrial Cancer and its Effects on Serum CA19-9,HE4 and TGF-β1[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(3): 337-339.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.03.005 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I3/337

[1] 刘向玲,张蓉蓉. 术后化疗-放疗-化疗治疗子宫内膜癌的疗效及对患者肿瘤标志物的影响[J].医学临床研究,2022,39(7):1104-1106.
[2] RAJKUMAR S,NATH R,LANE G,et al.Advanced stage(ⅢC/Ⅳ)endometrial cancer:Role of cytoreduction and determinants of survival[J].Eur J Obstet Gynecol Reprod Biol,2019,234:26-31.
[3] KHOURI O R,FREY M K,MUSA F,et al. Neoadjuvant chemotherapy in patients with advanced endometrial cancer[J].Cancer Chemother Pharmacol,2019,84(2):281-285.
[4] NITHIN K U.CA125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding[J].Afr Health Sci,2018,18(4):972-978.
[5] 孙燕,周际昌. 临床肿瘤内科手册[M]. 北京:人民卫生出版社,2003:97-107.
[6] DE LANGE N M,EZENDAM N P M,KWON J S,et al. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer[J].Curr Oncol,2019,26(2):e226-e232.
[7] LU K H,BROADDUS R R. Endometrial cancer[J].N Engl J Med,2020,383(21):2053-2064.
[8] RABINOVICH A. Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma:a glimmer of hope in select patients[J].Arch Gynecol Obstet,2016,293(1):47-53.
[9] ELIES A,RIVIÈRE S,POUGET N,et al. The role of neoadjuvant chemotherapy in ovarian cancer[J].Expert Rev Anticancer Ther,2018,18(6):555-566.
[10] NOMURA H,AOKI D,MICHIMAE H,et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression:a randomized clinical trial[J].JAMA Oncol,2019,5(6):833-840.
[11] NI T,LIU Y,HUANG Y,et al. Hysteroscopy combined dilatation and curettage,serum CA125 and CA19-9 play an important role in preserving fertility or endocrine function for early-stage endometrial cancer patients[J].Eur J Gynaecol Oncol,2017,38(1):49-53.
[12] BIAN J. Clinical significance of serum HE4,CA125,CA724,and CA19-9 in patients with endometrial cancer[J].Technol Cancer Res Treat,2017,16(4):435-439.
[13] 董飞天,李瑞宁. 甲磺酸阿帕替尼治疗晚期卵巢癌的疗效及对血清HE4、hK10、CA125水平的影响[J].医学临床研究,2022,39(7):1054-1057.
[14] HUANG X,WANG X,SHANG J,et al. Estrogen related receptor alpha triggers the migration and invasion of endometrial cancer cells via up regulation of TGFB1[J].Cell Adh Migr,2018,12(6):538-547.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(1): 145-147.